(1R,3R,6R)-6-((3aR,4S,7aR)-4-hydroxy-7a-methyloctahydroinden-1-yl)-2,10-dimethylundecane-2,3,10-triol | 792959-58-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (1R,3R,6R)-6-((3aR,4S,7aR)-4-hydroxy-7a-methyloctahydroinden-1-yl)-2,10-dimethylundecane-2,3,10-triol
• 英文别名: [1R,3aR,4S,7aR]-6(R)-[4-hydroxy-7a-methyl-octahydro-inden-1-yl]-2,10-dimethyl-undecane-2,3(R),10-triol；[1R,3aR,4S,7aR]-6(R)-(4-hydroxy-7a-methyl-octahydroinden-1-yl)-2,10-dimethyl-undecane-2,3(R),10-triol；6(R)-[(1R,3aR,4S,7aR)-4-hydroxy-7a-methyloctahydroinden-1-yl]-2,10-dimethylundecane-2,3(R),10-triol；[1R,3aR,4S,7aR]-6(R)-(4-Hydroxy-7a-methyl-octahydro-inden-1-yl)-2,10-dimethyl-undecane-2,3(R),10-triol；(3R,6R)-6-[(1R,3aR,4S,7aR)-4-hydroxy-7a-methyl-1,2,3,3a,4,5,6,7-octahydroinden-1-yl]-2,10-dimethylundecane-2,3,10-triol
• CAS: 792959-58-1
• 化学式: C₂₃H₄₄O₄
• 分子量: 384.6
• InChiKey: OCLCRGZDMQEEPI-TYUQVFQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  80.9
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1R,3R,6R)-6-((3aR,4S,7aR)-4-hydroxy-7a-methyloctahydroinden-1-yl)-2,10-dimethylundecane-2,3,10-triol 在 吡啶 、 咪唑 、 lithium aluminium tetrahydride 、 重铬酸吡啶 、 正丁基锂 、 Celite 、 4-甲基苯磺酸吡啶 、 溶剂黄146 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 环己烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 142.84h， 生成 [1R,3aR,7aR,4E]-4-{2(Z)-[3(S),5(R)-bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohexylidene]-ethylidene}-7a-methyl-1-[5-methyl-1(R)-(4-methyl-4-trimethylsilanyloxy-pentyl)-4(R)-[dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-5-trimethylsilanyloxy-hexyl]-octahydro-indene
  参考文献：
  名称：

  Calcitriol Derivatives with Two Different Side Chains at C-20. II. Diastereoselective Syntheses of the Metabolically Produced 24(R)-Hydroxygemini

  摘要：

  Vitamin D derivatives containing two side chains emanating at C-20 are known as gemini. We have recently synthesized two gemini which are related to calcitriol and 19-norcalcitriol containing two identical side chains. The metabolism of these species involves 24(R)hydroxylation on one of the side chains. To determine the outcome of this diastereospecific transformation, we synthesized both C-20 epimeric pairs containing the 24(R)-hydroxy group in the gemini and 19-norgemini series. On the basis of the availability of these reference compounds, it was shown that the metabolic hydroxylation occurred at the pro-R side chain in both gemini compounds. In comparison to the parent compounds, the 24-hydroxygemini required higher doses to increase blood calcium levels in mice and to suppress INF-gamma release in MLR.

  DOI：

  10.1021/jm049340b
• 作为产物：
  描述：

  (1R,3R,6R)-6-[(3aR,4S,7aR)-4-(tert-butyldimethylsilanyloxy)-7a-methyloctahydroinden-1-yl]-2,10-dimethylundecane-2,3,10-triol 在 六氟合硅酸 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 反应 3.25h， 以85%的产率得到(1R,3R,6R)-6-((3aR,4S,7aR)-4-hydroxy-7a-methyloctahydroinden-1-yl)-2,10-dimethylundecane-2,3,10-triol
  参考文献：
  名称：

  [EN] USE OF VITAMIN D COMPOUNDS FOR THE PREVENTION OR TREATMENT OF CHRONIC PROSTATITIS
  [FR] UTILISATION DE COMPOSES DE VITAMINE D POUR LA PREVENTION OU LE TRAITEMENT DE LA PROSTATITE CHRONIQUE

  摘要：

  维生素D化合物在慢性前列腺炎的预防或治疗中的使用，以及相关方法、药物配方和工具包。

  公开号：

  WO2006035075A1

文献信息

• GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Adorini Luciano

  公开号：US20080280859A1

  公开（公告）日：2008-11-13

  The invention provides Gemini vitamin D 3 compounds, methods for using the compounds to treat vitamin D3 associated states and pharmaceutical compositions containing the compounds.

  这项发明提供了双子座维生素D3化合物，使用这些化合物治疗与维生素D3相关疾病的方法以及含有这些化合物的药物组合物。
• Treatment of Interstitial Cystitis with Vitamin D Compounds
  申请人：Colli Enrico

  公开号：US20080039434A1

  公开（公告）日：2008-02-14

  There is provided according to the invention a vitamin D compound for use in the prevention and/or treatment of interstitial cystitis. Also provided is a method for preventing and/or treating interstitial cystitis by administering an effective amount of a vitamin D compound.

  本发明提供了一种维生素D化合物，用于预防和/或治疗间质性膀胱炎。同时提供了一种方法，通过给予有效剂量的维生素D化合物来预防和/或治疗间质性膀胱炎。
• Methods for treating bladder dysfunction
  申请人：Colli Enrico

  公开号：US20070054887A1

  公开（公告）日：2007-03-08

  There is provided according to the invention the use of Vitamin D compounds such as 1-alpha-fluoro-25-hydroxy-16,23e-diene-26,27-bishomo-20-epi-cholecalciferol in the prevention or treatment of bladder dysfunction.

  本发明提供了使用维生素D类化合物，例如1-α-氟-25-羟基-16,23-二烯-26,27-双同型-20-表-胆钙化醇，用于预防或治疗膀胱功能障碍。
• Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer
  申请人：Adorini Luciano

  公开号：US20080293647A1

  公开（公告）日：2008-11-27

  There is provided according to the invention a method of treating a patient with bladder cancer by administering a effective amount of a vitamin D compound in combination with one or more other antiproliferative agents. Also provided are uses of a vitamin D compound in combination with one or more other antiproliferative agents and compositions for use in the method.

  根据本发明提供了一种治疗患有膀胱癌的患者的方法，该方法是通过同时给予一种有效量的维生素D化合物和一种或多种其他抗增殖剂。还提供了维生素D化合物与一种或多种其他抗增殖剂的用途以及用于该方法的组合物。
• WO2006/51106
  申请人：——

  公开号：——

  公开（公告）日：——